Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group:

  • Dickson R, Bagust A, Beale S et al. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation positive malignant melanoma: A Single Technology Appraisal. Liverpool Reviews and Implementation Group, 2012.

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were also invited to comment on the appraisal consultation documents. Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • Roche Products (vemurafenib)

II Professional/specialist and patient/carer groups:

  • British Association of Dermatologists

  • British Association of Skin Cancer Nurse Specialists

  • Factor 50

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)

  • United Kingdom Clinical Pharmacy Association

III Other consultees:

  • Department of Health

  • NHS Birmingham East and North

  • Welsh Assembly Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • Bayer (dacarbazine)

  • Bristol‑Myers Squibb (ipilimumab)

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Health Improvement Scotland

  • Liverpool Reviews & Implementation Group, University of Liverpool

  • National Collaborating Centre for Cancer

  • National Institute for Health Research Health Technology Assessment Programme

C The following individuals were selected from clinical specialist and patient expert nominations from the non‑manufacturer/sponsor consultees and commentators. They gave their expert personal view on vemurafenib by attending the Committee discussions and providing written evidence to the Committee. They were also invited to comment on the appraisal consultation documents.

  • Dr Louise Fearfield, Consultant Dermatologist, nominated by an organisation representing the British Association of Dermatologists – clinical specialist

  • Dr Paul Lorigan, Senior Lecturer in Medical Oncology, nominated by and organisation representing Roche and Royal College of Physicians – clinical specialist

  • Professor Martin Gore, Consultant Medical Oncologist nominated by an organisation representing the Royal College of Physicians – clinical specialist

  • Mrs Gillian Nuttall, CEO & Founder, nominated by an organisation representing Factor 50 – patient expert

  • Mr Steve Chalk, nominated by an organisation representing Factor 50 – patient expert

D Representatives from the following manufacturer/sponsor attended the Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Roche Products

  • National Institute for Health and Care Excellence (NICE)